# Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review

## TL;DR

A patient with a specific type of leukemia achieved deep remission using avapritinib, a drug targeting KIT mutations.

## Contribution

This case report demonstrates avapritinib's potential as a targeted therapy for relapsed t(8;21) AML with KIT mutations.

## Key findings

- Avapritinib monotherapy induced rapid and deep remission in a patient with KIT D816H-mutated t(8;21) AML.
- The patient had relapsed after an allogeneic stem cell transplant but responded well to avapritinib.
- The findings suggest avapritinib could be a promising treatment for relapsed t(8;21) AML with KIT mutations.

## Abstract

Acute myeloid leukemia (AML) with t(8;21) is a subset of core binding factor AML and is considered to be favorable risk disease in patients receiving intensive cytarabine based chemotherapy. However, relapse remains a significant clinical challenge. Mutations in KIT, which frequently co-occur in t(8;21) AML, have been associated with worse relapse free and overall survival. Avapritinib is a novel tyrosine kinase inhibitor targeting KIT mutations that is approved for systemic mastocytosis but doesn’t currently have an established role in the treatment of AML. We present a case of a patient with extensively treated KIT D816H-mutated t(8;21) AML who experienced relapse after an allogeneic hematopoietic stem cell transplant and achieved a deep remission rapidly with avapritinib monotherapy. This case highlights the potential role of avapritinib as a targeted therapy for relapsed t(8;21) AML with KIT mutations, warranting further clinical investigation.